ANI Pharmaceuticals offers to acquire Egetis Therapeutics for $560M

ANI Pharmaceuticals announced a recommended public offer to acquire Egetis Therapeutics for SEK 11.25 per share, totaling approximately SEK 5.6 billion ($560 million). The acquisition is unanimously recommended by Egetis' board.

“This proposed acquisition further accelerates our transformation with a substantial majority of our revenues expected to be derived from higher margin rare disease products by decade’s end.”investor.anipharmaceuticals.com

• 1 source
• investor.anipharmaceuticals.comANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business - ANI Pharmaceuticals, Inc.Nov 5, 2026

Summarized from public sources; check the original articles before acting on it.